Archive
1250 articles, sorted by publication time.
Innate Pharma gains the resources needed for a Phase 3 trial through a licensing deal, while Sobi obtains a late-stage antibody targeting KIR3DL2; the real test is whether early clinical signals can be translated into accelerated approval and confirmatory evidence.
Four large language models underwent a structured critical appraisal test involving 24 studies on breast cancer and viruses. The overall agreement distribution of the GPT-5 series was close to that of domain experts, but methodological assessment, contradictions within full texts, and hallucinations by smaller models delineated the limits of automated evidence review.
Researchers used genomic models to design complete viral sequences, validating 16 of 285 candidates as bacteriophages capable of infecting Escherichia coli. The results cross the threshold between computer prediction and biological function, but clinical treatment remains far off, while governance of virus design is also coming under pressure.
A research team immobilized peptides on a nanopore, repeatedly measuring them while removing amino acids one by one. The method can already distinguish single-site substitutions, post-translational modifications, and non-natural residues, but considerable engineering work remains before it can directly analyze complex biological samples.
A randomized Phase 2 trial showed that a cannabinoid combination can rapidly relieve agitation in people with dementia eligible for hospice care, with effects lasting through 12 weeks; however, the findings currently come mainly from a conference presentation, and the safety disparity and scope of applicability still require evaluation in a full paper.
A longitudinal multi-omics study maps a relay mechanism after cancer cells take hold in the lungs: a small number of cells first evade clearance through a PHGDH-related state, after which macrophages create an immune-protected zone; blocking either stage reduces metastatic growth in mice.
A personalized gene therapy enrolling just one patient proceeded to human use before animal toxicology warning signs had been fully clarified; after the participating girl died, the trial registry, paper, and funding disclosures still failed to present a complete account of what happened.
A 157-person phase 2 trial showed that the recurrence-free advantage of intismeran plus pembrolizumab persisted through five years; the signal is encouraging, but the small trial is not yet sufficient to establish a survival benefit or rewrite the standard of care.
National data from more than 28,000 patients show that frail older people, young women, and residents of disadvantaged areas are particularly likely to enter the diagnostic pathway through emergency hospital admission; the findings highlight an early-detection gap jointly created by nonspecific symptoms and healthcare accessibility.
The first telomere-to-telomere brown rat assembly, combined with eight commonly used laboratory strains, incorporates sequences and genes missing from previous reference genomes. It could improve the ability to pinpoint disease-associated variants, but there is still some way to go before it can be shown that these models better predict human responses.
Although the Phase 3 trial successfully increased blood pyrophosphate levels in patients, it did not improve radiographic signs of rickets or growth measures. BioMarin ultimately discontinued development across all indications, bringing the core asset it acquired for $270 million a year earlier to a premature end.
The experimental small molecule CS18 targets TopBP1, a protein involved in DNA repair and tumor signaling. In preclinical studies, it enhanced the effects of PARP inhibitors and resensitized drug-resistant lung cancer cells to osimertinib; key pharmacological and safety questions must still be resolved before human trials can begin.